Advertisement

Journal of Gastroenterology

, Volume 29, Issue 4, pp 531–543 | Cite as

Primary sclerosing cholangitis

  • Yoshiyuki Ueno
  • Nicholas F. LaRusso
Article

Keywords

Public Health Internal Medicine Colorectal Surgery Cholangitis Primary Sclerosing Cholangitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    LaRusso NF, Wiesner RH, Ludwig J, et al. Primary sclerosing cholangitis. N Engl J Med 1984;310:899–903.PubMedGoogle Scholar
  2. 2.
    Wiesner RH, LaRusso NF. Climcopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology 1980;79:200–206.PubMedGoogle Scholar
  3. 3.
    Chapman RW, Arborgh BA, Rhodes JM, et al. Primary sclerosing cholangitis: A review of its clinical features, cholangiopathy, and hepatic histology. Gut 1980;21:870–877.PubMedGoogle Scholar
  4. 4.
    MacCarty RL, LaRusso NF, Wiesner RH, et al. Primary sclerosing cholangitis: Findings of cholangiography and pancreatography. Radiology 1983;149:39–44.PubMedGoogle Scholar
  5. 5.
    Snook JA, Chapman RW, Fleming K, et al. Anti-neutrophil nuclear antibody in ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. Clin Exp Immunol 1989;76:30–33.PubMedGoogle Scholar
  6. 6.
    Duerr RH, Targan SR, Landers CJ, et al. A link between primary sclerosing cholangitis and ulcerative cholitis. Gastroenterology 1991;100:1385–1391.PubMedGoogle Scholar
  7. 7.
    Ludwig JH. Surgical pathology of the syndrome of primary sclerosing cholangitis. Am J Surg Pathol 1989;13:43–49PubMedGoogle Scholar
  8. 8.
    Ludwig J. Small-duct primary sclerosing cholangitis. Semin Liver Dis 1991;11:11–17PubMedGoogle Scholar
  9. 9.
    White TT, Hart MJ. Primary sclerosing cholangitis. Am J Surg 1987;153:439–443.CrossRefPubMedGoogle Scholar
  10. 10.
    Shepard HA, Selby WS, Chapman RW, et al. Ulcerative colitis and persistent liver dysfunction. Q J Med 1983;52:503–513.Google Scholar
  11. 11.
    Porayko MK, LaRusso NF, Wiesner RH. Primary sclerosing cholangitis: A progressive disease? Semin Liver Dis 1991;11: 18–25.PubMedGoogle Scholar
  12. 12.
    Utsunomiya T. Etiology of ulcerative colitis (in Japanese). Geka (Surgery) 1992;54:13–20.Google Scholar
  13. 13.
    Wiesner RH, Grambsch PM, Dickson ER, et al. Primary sclerosing cholangitis: Natural history, prognostic factors and survival analysis. Hepatology 1989;10:430–436.PubMedGoogle Scholar
  14. 14.
    Helzberg JH, Peterson JM, Boyer JL, Improved survival with primary sclerosing cholangitis. A review of the clinicopathologic features and comparison of symptomatic and asymptomatic patients. Gastroenterology 1980;79:200–206.Google Scholar
  15. 15.
    Warren KW, Athnassiades S, Monge JI. Primary sclerosing cholangitis. Am J Surg 1966;111:23–38.CrossRefPubMedGoogle Scholar
  16. 16.
    Lefkowitch JH, Martin EC. Primary sclerosing cholangitis. A study of 42 cases. Am J Surg 1986;111:23–38.Google Scholar
  17. 17.
    Wiesner RH, Ludwig J, LaRusso NF, et al. Diagnosis and treatment of primary sclerosing cholangitis. Semin Liver Dis 1985;5:241–253.PubMedGoogle Scholar
  18. 18.
    Wiesner RH, Ludwig J, LaRusso NF, et al. Comparison of the clinicopathologic features of primary sclerosing cholangitis and primary biliary cirrhosis. Gastroenterology 1985;95:1395–1398.Google Scholar
  19. 19.
    Thorpe MEC, Scheuer PJ, Sherlock S. Primary sclerosing cholangitis in ulcerative colitis. Gut 1967;8:435–448.PubMedGoogle Scholar
  20. 20.
    Schrumpf E, Fausa O, Kolmannskog F, et al. Sclerosing cholangitis in ulcerative colitis. A follow-up study. Scand J Gastroenterol 1982;17:33–39.PubMedGoogle Scholar
  21. 21.
    Kashihara T, Sibamoto S, Fujimori E, et al. Two cases of primary sclerosing cholangitis. Report of two cases and review of the recent literature. Gastroenterol Endosc 1990;32:1194–1204.Google Scholar
  22. 22.
    Cangemi JR, Wiesner RH, Beaver SJ, et al. Effect of proctocolectomy for chronic ulcerative colitis on the natural history of primary sclerosing cholangitis. Gastroenterology 1989;96:790–794.PubMedGoogle Scholar
  23. 23.
    Rosen CB, Nagorney DM, Wiesner RH, et al. Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg 1991;213:21–25.PubMedGoogle Scholar
  24. 24.
    Rosen CB, Nagorney DM. Cholangiocarcinoma complicating primary sclerosing cholangitis. Semin Liver Disease 1991;11:26–30.Google Scholar
  25. 25.
    Wiesner RH, Larusso NF, Doozois RR, et al. Peristomal varices after protocolectomy in patients with primary sclerosing cholangitis. Gastroenterology 1986;90:316–322.PubMedGoogle Scholar
  26. 26.
    Balasubramanian K, Wiesner RH, LaRusso NF. Primary sclerosing cholangitis with normal serum alkaline phosphatase activity. Gastroenterology 1988;95:1395–1398.Google Scholar
  27. 27.
    Gross JB, Ludwig J, Wiesner RH, et al. Abnormalities in tests of copper metabolism in primary sclerosing cholangitis. Gastro enterology 1985;89:272–278.Google Scholar
  28. 28.
    Lichtman SN, Sartor RB. Hepatobiliary injury associated with experimental small-bowel bacterial overgrowth in rats. Immunol Res 1991;10:528–531.PubMedGoogle Scholar
  29. 29.
    Lichtman SN, Okoruwa EE, Keku J, et al. Degradation of endogenous bacterial cell wall polymers by the muralytic enzyme mutanolysin prevents hepatobiliary injury in genetically susceptible rats with experimental intestinal bacterial overgrowth. J Clin Invest 1992;90:1313–1322.PubMedGoogle Scholar
  30. 30.
    Ueno Y, Phillips JO, Ludwig J, et al. Nonsuppurative cholangitis induced in rodents by cholangiocyte immunization: An experimental model for immune cholangiopathies. Hepatology 1993;18:170A.CrossRefGoogle Scholar
  31. 31.
    Jorge AD, Esley C, Anumada J. Family incidence of primary sclerosing cholangitis associated with immunological diseases. Endoscopy 1987;19:114–117.PubMedGoogle Scholar
  32. 32.
    Quigley EM, LaRusso NF, Ludwig J, et al. Familial occurence of primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1983;85:1160–1165.PubMedGoogle Scholar
  33. 33.
    Chapman RW, Varghese Z, Gaul R, et al. Association of primary sclerosing cholangitis with HLA-B8, Gut 1983;24:38–41.PubMedGoogle Scholar
  34. 34.
    Schrumpf E, Fausa O, Forre O, et al. HLA antigens and immunoregulatory T cells in ulcerative colitis assciated with hepatobiliary disease. Scand J Gastroenterol 1982;17:187–191.PubMedGoogle Scholar
  35. 35.
    Sherlock S. The syndrome of disappearance bile ducts. Lancet 1987;II:493–496.Google Scholar
  36. 36.
    Terblanche JA, Allison HE, Nothover JMA. An ischemic basis for biliary strictures. Surgery 1983;94:52–57.PubMedGoogle Scholar
  37. 37.
    LaRusso NF, Wiesner RH, Ludwig J, et al. Prospective trial of penicillamine in primary sclerosing cholangitis. Gastroenterology 1988;95:1036–1042.PubMedGoogle Scholar
  38. 38.
    Carry JB. Bile acids, cirrhosis and human evolution. Gastroenterology 1964;46:469–481.Google Scholar
  39. 39.
    Siegel JH, Barnes S, Morris JS. Bile acids in liver disease associated with inflammatory bowel disease. Digestion 1977;15: 469–481.PubMedGoogle Scholar
  40. 40.
    Dew MJ, Henegowen GP, van B Huybregts AWM, et al. Hepatotoxic effect of bile acids in inflammatory bowel disease. Gastroenterology 1980;78:1393–1401.PubMedGoogle Scholar
  41. 41.
    Holzbach RT, Marsh ME, Freedman MR, et al. Portal vein bile acids in patients with severe inflammatory bowel disease. Gut, 1980;21:428–435.PubMedGoogle Scholar
  42. 42.
    Kemeny MM, Battifora H, Blayney DW, et al. Sclerosing cholangitis after continuous hepatic artery infusion of FUDR. Ann Surg 1985;202:176–181.PubMedGoogle Scholar
  43. 43.
    Kemeny N, Daly J, Erichamn B, et al. Intra-hepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med 1987;107:459–465.PubMedGoogle Scholar
  44. 44.
    Ludwig J, Kim CH, Weisner RH, et al. Floxuridine-induced sclerosing cholangitis: An ischemic cholangiopathy? Hepatology 1989;9:215–218.PubMedGoogle Scholar
  45. 45.
    Shea WJJ, Demas BE, Goldberg HI, et al. Sclerosing cholangitis associated with hepatic arterial FUDR chemotherapy: Radiographic-histologic correlation. Am J Roentgenol 1986; 146:717–721.Google Scholar
  46. 46.
    Minuk GY, Rascain N, Paul RW, et al. Reovirus type 3 infection in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 1987;5:8–13.CrossRefPubMedGoogle Scholar
  47. 47.
    Rosser BG, Hay JE, Espy MJ, et al. Evidence against a pathogenic role for cytomegalovirus (CMV) in primary sclerosing cholangitis (PSC). Hepatology 1992;16:193A.Google Scholar
  48. 48.
    Morecki R, Glaser JH, Cho S, et al. Biliary atresia and reovirus type 3 infection. N Engl J Med 1982;307:481–484.PubMedGoogle Scholar
  49. 49.
    Bangaru B, Morecki R, Glaser JH, et al. Comparative studies of biliary atresia in the human newborn and reovirus-induced cholangitis in weanling mice. Lab Invest 1980;43:456–462.PubMedGoogle Scholar
  50. 50.
    Minuk GY, Paul RW, Lee PWK. The prevalence of antibodies to reovireas type 3 in adults with idiopathic cholestatic liver disease. J Med Virol 1985;16:55–60.PubMedGoogle Scholar
  51. 51.
    Bodenheimer HCJ, LaRusso NF, Thayer WRJ, et al. Elevated circulating immune complexes in primary sclerosing cholangitis. Hepatology 1983;3:150–154.PubMedGoogle Scholar
  52. 52.
    Minuk GY, Angus M, Brickman CM, et al. Abnormal clearance of immune complexes from the circulation of patients with primary sclerosing cholangitis. Gastroenterology 1985; 88:166–170.PubMedGoogle Scholar
  53. 53.
    Senaldi G, Donaldson PT, Margin S, et al. Activation of the complement system in primary sclerosing cholangitis. Gastroenterology 1989;97:1430–1434.PubMedGoogle Scholar
  54. 54.
    Lindor KD, Wiesner RH, Katzmann JA, et al. Lymphocyte subsets in primary sclerosing cholangitis. Dig Dis Sci 1987;32: 720–725.PubMedGoogle Scholar
  55. 55.
    Snook JA, Chapman RW, Sachdev GK, et al. Peripheral blood and portal tract lymphocyte populations in primary sclerosing cholangitis. J Hepatol 1989;9:36–41.CrossRefPubMedGoogle Scholar
  56. 56.
    Whiteside RL, Lasky S, Si L, et al. Immunologic analysis of mononuclear cells in liver tissues and blood of patients with primary sclerosing cholangitis. Hepatology 1985;5:468–474.PubMedGoogle Scholar
  57. 57.
    van de Oord JJ, Sciot R, Desmet VJ. Expression of MHC products by normal and abnormal bile duct epithelium. J Hepatol 1986;3:310–317.PubMedGoogle Scholar
  58. 58.
    Chapman RW, Kelly PM, Heryet A, et al. Expression of HLA-DR antigens on bile duct epithelium in primary sclerosing cholangitis. Gut 1988;29:422–427.PubMedGoogle Scholar
  59. 59.
    Broom U, Galumann H, Hulterantz R, et al. Distribution of HLA-DR, HLA-DP, and HLA-DQ antigens in liver tissue from patients with primary sclerosing cholangitis. Scan J Gastroenterol 1990;25:54–58.Google Scholar
  60. 60.
    Mayer L, Eisenhardt D, Salomon P, et al. Expression of class II molecules on intestinal epithelial cells in humans. Differences between normal and inflammatory bowel disease. Gastroenterology 1991;100:3–12.PubMedGoogle Scholar
  61. 61.
    Phillips JO, Vroman B, Ueno Y, et al. Induction of functional MHC class II protein permits redent cholangiocytes to behave as antigen presenting cells. Gastroenterology 1994;106: 961A.Google Scholar
  62. 62.
    Ludwig J, Wiesner RH, LaRusso NF. Idiopathic adulthood ductopenia: A cause of chronic liver disease and biliary cirrhosis. J Hepatol 1988;7:193–199.CrossRefPubMedGoogle Scholar
  63. 63.
    Farrant JM, Hayllar KM, Wilkinson ML, et al. Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology 1991;100:1710–1717.PubMedGoogle Scholar
  64. 64.
    Porayko MK, Wiesner RH, LaRusso NF, et al. Patients with asymptomatic primary sclerosing cholangitis frequently have progressive disease. Gastroenterology 1990;98:1594–1602.PubMedGoogle Scholar
  65. 65.
    Chapman RWG, Burroughs AK, Bass NM, et al. Long-standing asymptomatic primary sclerosing cholangitis. Report of three cases. Dig Dis Sci 1981;26:778–782.CrossRefPubMedGoogle Scholar
  66. 66.
    Dickson ER, Murtaugh PA, Wiesner RH, et al. Primary sclerosing cholangitis: Refinement and validation of survival models. Gastroenterology 1992;103:1893–1901.PubMedGoogle Scholar
  67. 67.
    Kaplan MM, Medical approach to primary sclerosing cholangitis. Semin Liver Dis 1991;11:56–63.PubMedGoogle Scholar
  68. 68.
    Lindor KD, LaRusso NF, Wiesner RH. Prednisone and colchicine are not of benefit after 2 years in patients with primary sclerosing cholangitis. Hepatology 1989;10:638.Google Scholar
  69. 69.
    Myers RN, Cooper TH, Padis N. Primary sclerosing cholangitis. Complete gross and histologic reversal after long-term steroid therapy. Am J Gastroenterol 1970;53:527–538.PubMedGoogle Scholar
  70. 70.
    Burgert SC, Brown BP, Kirkpatrick RB, et al. Positive corticosteroid response in patients with primary sclerosing cholangitis. Hepatology 1984;10:638.Google Scholar
  71. 71.
    Javett SL. Azathioprine in primary sclerosing cholangitis. Lancet 1971;I:810.Google Scholar
  72. 72.
    Wagner A. Azathioprine treatment in primary sclerosing cholangitis. Lancet 1971;II:663–664.Google Scholar
  73. 73.
    Wiesner RH, Steiner B, LaRusso NF, et al. A controlled clinical trial evaluating cyclosporine in the treatment of primary sclerosing cholangitis. Hepatology 1991;14:63A.CrossRefGoogle Scholar
  74. 74.
    Kaplan MM, Arora S, Pincus SH. Primary sclerosing cholangitis and low-does oral pulse methotrexate therapy. Clinical and histologic response. Ann Intern Med 1978;106:231–235.Google Scholar
  75. 75.
    Beuers U, Spengler U, Kruis W, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: A placebo-controlled trial. Hepatology 1992;16:707–714.PubMedGoogle Scholar
  76. 76.
    O'Brien CB, Senior JR, Arora-Mirchandini R, et al. Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: A 30-month pilot study. Hepatology 1992;14:838–847.Google Scholar
  77. 77.
    Van Thiel DH, Wright HI, Gavaler JS. Ursodeoxycholic acid (UDCA) therapy for primary sclerosing cholangitis (PSC): Preliminary report of a randomized controlled trial. Hepatology 1992;16:71A.Google Scholar
  78. 78.
    Lo SK, Herrmann R, Chapman RW, et al. Ursodeoxycholic acid in primary sclerosing cholangitis: A double-blind placebo controlled trial. Hepatology 1992;16:92A.Google Scholar
  79. 79.
    May GR, Bender CE, LaRusso NF, et al. Nonoperative dilatation of dominant strictures in primary sclerosing cholangitis. Am J Radiol 1985;145:1061–1064.Google Scholar
  80. 80.
    Bender CE, Wiesner RH, LeRoy AJ, et al. Clinical improvement following percutaneous balloon dilatation of dominant bile duct strictures in primary sclerosing cholangitis. Gastroenterology 1992;102:A780.Google Scholar
  81. 81.
    Nichols JC, Gores GJ, LaRusso NF, et al. Diagnostic role of CA19-9 for cholangiocarcinoma in primary sclerosing cholangitis. Hepatology 1992;16:62A.Google Scholar
  82. 82.
    Wiesner RH, Porayko MK, Dickson ER, et al. Selection and timing of liver transplantation in primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology 1992;16:1290–1299.CrossRefPubMedGoogle Scholar
  83. 83.
    LaRusso F, Wiesner RH. Liver and biliary diseases. Baltimore: Williams and Wilkins, 1992.Google Scholar
  84. 84.
    Olsson R, Danielsson A, Jarnerot G, et al. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 1991;100:1319–1323.PubMedGoogle Scholar
  85. 85.
    Fausa O, Schrumpf E, Elgjo K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin Liver Dis 1991;11:31–39.PubMedGoogle Scholar
  86. 86.
    Sivak MJ, Farmer RG, Lalli AF. Sclerosing cholangitis: Its increasing frequency of recognition and association with inflammatory bowel disease. J Cli Gastroenterology 1981;3:261–266.Google Scholar
  87. 87.
    Aadland E, Schrumpt E, Fausa O, et al. Primary sclerosing cholangitis: A long-term follow-up study. Scand J Gastroenterol 1987;22:655–664.PubMedGoogle Scholar
  88. 88.
    Stockbrügger RW, Olsson R, Jaup B, et al. Forty-six patients with primary sclerosing cholangitis. Radiological bile duct changes in relationship to clinical course and concomitant inflammatory bowel disease. Hepatogastroenterol 1988;35:289–294.Google Scholar
  89. 89.
    Rabinovitz M, Gavaler JS, Schade RR, et al. Does primary sclerosing cholangitis occuring in association with inflammatory bowel disease differ from that occuring in the absence of inflammatory bowel disease? A study of sixty-six subjects. Hepatology 1990;11:7–11.PubMedGoogle Scholar
  90. 90.
    Wiezner RH, LaRusso NF. Primary sclerosing cholangitis. In: Bouchiere I. ed. Textbook of Gastroenterology. Bailliere Tindall, London (in press)Google Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • Yoshiyuki Ueno
    • 1
  • Nicholas F. LaRusso
    • 1
    • 2
  1. 1.Center for Basic Research in Digestive Diseases, Division of Gastroenterology and Internal MedicineMayo Clinic and Mayo FoundationRochesterUSA
  2. 2.Department of Biochemistry and Molecular BiologyMayo Clinic and Mayo FoundationRochesterUSA

Personalised recommendations